ISA-101 Drug Asset Due Diligence Report 2026

This ISA-101 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether ISA-101 can convert its Shared antigen vaccine, Therapeutic vaccine profile and Not disclosed biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	ISA-101 (query alias: ISA-101)
Modality / target	Shared antigen vaccine, Therapeutic vaccine; Not disclosed; Immunostimulants
Highest global status	Phase 2
Originator	ISA Pharmaceuticals BV
Active developers	The University of Texas MD Anderson Cancer Center, ISA Pharmaceuticals BV, Shin Nippon Biomedical Laboratories, Ltd.

The MCP disease footprint includes Human Papillomavirus-Related Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Oropharyngeal Neoplasms. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
ChiCTR2400081846	Early Phase 1	Pending	500	Primary endpoint not disclosed in English source
NCT04713046	Phase 1/2	Active, not recruiting	24	Primary endpoint not disclosed in English source
NCT04646005	Phase 2	Completed	113	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Phase II Study Evaluating HPV-16 Vaccination (ISA101b) and Pembrolizumab Plus Cisplatin Chemoradiotherapy for "Intermediate Risk" HPV-16 Associated Head and Neck Squamous Cell Carcinoma (HNSCC)

Phase 2; n=18; evaluation: Not stated in English source. Reported fields: Progression-free Survival (PFS) at 2 Years = 75.5 % (95%CI, 54.9 - 100.0)

A Phase 2 Study of Cemiplimab, an Anti-PD-1 Monoclonal Antibody, and ISA101b Vaccine in Patients With Recurrent/Metastatic HPV16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy

Phase 2; n=113; evaluation: Not stated in English source. Reported fields: ORR = 17.7 % (95%CI, 10.7 - 24.7)

Results of a randomized, double-blind, placebo-controlled, phase 2 study (OpcemISA) of the combination of ISA101b and cemiplimab versus cemiplimab for recurrent/metastatic (R/M) HPV16-positive oropharyngeal cancer (OPC).

Phase 2; n=198; evaluation: Positive. Reported fields: ORR = 25.3 % ; ORR = 22.9 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

ISA-101 addresses Human Papillomavirus-Related Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Oropharyngeal Neoplasms. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Shared antigen vaccine, Therapeutic vaccine—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 1 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2017-12-18	Regeneron and ISA Pharmaceuticals Announce Strategic Immuno-Oncology Collaboration	Phase 2	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “HPV vaccine formulations comprising aluminum adjuvant and methods of producing same”. The milestone feed surfaced a patent-application signal described as “Papillomavirus vaccine compositions”. The milestone feed surfaced a patent-application signal described as “Papillomavirus vaccines”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Immunogenicity durability and clinically meaningful protection
Population selection, endpoint timing, and comparator relevance
Manufacturing consistency, distribution, and uptake

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO